10 月18 日(金)プログラム10 月19 日(土)プログラム10 月20 日(日)プログラム特別企画シンポジウムガイドラインセッションアフェレシスマニュアルレクチャー技術講習会E-ISFA Workshop 世界のアフェレシス事情一般演題(英語口演)一般演題(日本語口演)一般演題(ポスター)索引セミナー10月18日(金) Oct 18 th Room A Workshop ワークショップ 9:00〜10:30 E-ISFA Workshop Kyoto Chair Bernd Hohenstein Nephrological Center Villingen-Schwenningen Chair Wolfgang Ramlow Apheresis Center Rostock WS-01 Update on vasculitis treatment including plasma exchange Wladimir Szpirt Rigshospitale, Denmark WS-02 Lipoprotein(a): Delicate Risk Factor and Prime Target for Apheresis Wolfgang Ramlow Apheresis Center Rostock, Germany WS-03 Why should immunoadsorption be a therapy of continuing interest? Bernd Hohenstein Nephrological Center Villingen-Schwenningen, Germany Symposium 1 シンポジウム 1 CAR-T 血液治療 10:45〜12:15 Current State of CAR-T Therapies in the World Chair Chisa Yamada Department of Pathology, University of Michigan SY1-01 Current Status of CAR-T Therapy in the United States Nicole Aqui Department of Pathology and Laboratory Medicine, University of Pennsylvania, Phil- adelphia, Pennsylvania, USA SY1-02 Volker Witt SY1-03 Basic and clinical studies of CAR-T cell therapy in Japan Keiya Ozawa Division of Immuno-Gene & Cell Therapy (Takara Bio), Jichi Medical University, Tochigi, Japan Luncheon Seminar 1 12:30〜13:30 Sponsored by Novartis Pharma K.K. ノバルティスファーマ株式会社 Standard of Apheresis/Cell processing Site for CAR-T therapy Chair Peter Holman Global Apheresis Integration, Novartis Pharmaceuticals Corp. LS1-01 Institutional preparation for CAR-T Cell Therapy and Apheresis Peter Holman Global Apheresis Integration, Novartis Pharmaceuticals Corp. LS1-02 How to establish the management system for CAR-T therapy in Japan Masafumi Onodera Department of Human Genetics, National Center for Child Health and Development 21
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
WS-02 Lipoprotein(a):DelicateRiskFactorandPrimeTargetforApheresisWolfgang RamlowApheresis Center Rostock, Germany
WS-03 Whyshouldimmunoadsorptionbeatherapyofcontinuinginterest?Bernd HohensteinNephrological Center Villingen-Schwenningen, Germany
Symposium1 シンポジウム1 CAR-T 血液治療 10:45〜12:15
Current State of CAR-T Therapies in the World Chair ChisaYamada DepartmentofPathology,UniversityofMichigan
SY1-01 CurrentStatusofCAR-TTherapyintheUnitedStatesNicole AquiDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Phil-adelphia, Pennsylvania, USA
Standard of Apheresis/Cell processing Site for CAR-T therapy Chair PeterHolman GlobalApheresisIntegration,NovartisPharmaceuticalsCorp.
LS1-01 InstitutionalpreparationforCAR-TCellTherapyandApheresis Peter Holman Global Apheresis Integration, Novartis Pharmaceuticals Corp.
LS1-02 HowtoestablishthemanagementsystemforCAR-TtherapyinJapan Masafumi Onodera Department of Human Genetics, National Center for Child Health and Development
SL1-01 RemembranceofDr.AkiraYamamotoHarada-Shiba MarikoMolecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Japan
SL1-02 InMemoryofProf.AkiraYamamotoYoshihiro EndoDepartment of Clinical Nursing, Shiga University of Medical Science, Japan
Symposium2 シンポジウム2 LDL 15:30〜17:00
Registry of lipoprotein apheresisChair PatrickM.Moriarty UniversityofKansasMedicalCenterChair MarikoHarada-Shiba MolecularInnovationinLipidology,NationalCerebral
andCardiovascularCenterResearchInstitute
SY2-01 NorthAmericanLipoproteinApheresisRegistry(NALAR):Datacollectionde-signandrationalePatrick M. MoriartyUniversity of Kansas Medical Center, USA
SY2-02 RegistryofhomozygousfamilialhypercholesterolemiaMariko Harada-ShibaMolecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Japan
SY2-03 Beyondcholesterol,pleotropiceffectsoflipoproteinapheresis.Volker J. J. SchettlerCenter of Nephrology Goettingen GbR, Goettingen, Germany.
SY2-04 LDLapheresisinHeterozygousFamilialHypercholesterolemia:datafromtheFrenchRegistryofFamilialhypercholesterolemia(REFERCHOL)Antonio GalloCardiovascular Prevention Unit, University Hospital Pitie Salpetriere, France
ES1 TreatmentofinflammatoryboweldiseaseinEurope Rodolfo Sacco, MD, PhDGastroenterology and Endoscopy Digestive Unit –Foggia University Medical School - Italy
SY3-01 LeukocytapheresisasanAdjuncttoMedicationforInflammatoryBowelDiseaseKoji SawadaDirecter of Dojima General & Gastroenterology Clinic, Japan
SY3-02 GranulomonocytoapheresisastherapeuticoptionofIBDinEuropeRodolfoSaccoGastroenterology and Metabolic Disease Unit Cisanello Pisa University Hospital, Pisa, Italy
SY3-03 AdsorptiveGranulocyteandMonocyteApheresisintheTreatmentofInflamma-toryBoweldisease:TheFirstMulticenterStudyInChina.Yamin LaiPeking Union Medical College Hospital, China
SY3-04 Real-world experiences of cytapheresis therapy for ulcerative colitis; resultsfromlarge-scalemulticenterobservationalstudiesTaku KobayashiCenter for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
SY3-05 FactorsaffectingclinicalremissioninpatientswithulcerativecolitistreatedwithcytapheresistherapyShigeki BanbaDivision of Clinical Nutrition, Shiga University of Medical Science, Japan
SY4-01 Anovelleucoyteapheresisadsorptionsysteminrefractoryactiveulcerativeco-litisWolfgang Kruis Evangelisches Krankenhaus Köln Kalk ( Formerly active as chief physician ), Ger-many
SY4-02 Safetyandefficacyofsingleneedleleucocyteapheresisforulcerativecolitis:AretrospectiveanalysisYouichiro ShindoDivision of Gastroenterology Department of Medicine, Kurume University School of Medicine, Kurume, Japan
Department of Gastroenterology and Metabilism, Japan
SY4-04 EfficacyapheresisasmaintenancetherapyforpatientswithulcerativecolitisinaprospectivemulticentrerandomisedcontrolledtrialMakoto NaganumaDivision of Gastroenterology and Hepatology, Keio University School of Medicine, Japan
LS2-01 VascularpuncturesforGMAtreatment Hisashi Matono Department of medical engineer, Wakakusa-Daiichi Hospital
LS2-02 Tipsforensuringvascularaccessandmaintainingextracorporealcirculationinpediatricbloodpurificationtherapy Mariko Sawada Department of Pediatrics, Kurashiki Central Hospital
Symposium5 シンポジウム5 Dermatology皮膚疾患 15:30〜17:00
Advancement of Apheresis in DermatologyChair ShigakuIkeda DepartmentofDermatology,JuntendoUniversitySchoolofMedicineChair ChisaYamada TransfusionMedicine,DepartmentofPathology,
UniversityofMichigan,AnnArbor,Michigan,USA
SY5-01 Granulocyteandmonocyteadsorptionapheresisforgeneralizedpustularpsoria-sisMariko SeishimaDepartment of Dermatology, Gifu University Graduate School of Medicine, Japan
SY5-02 GranulocyteandmonocyteadsorptionapheresisforpsoriaticarthritisTakuroKanekuraDepartment of Dermatology, Kagoshima Universuty, Kagoshima, Japan
SY5-03 ExtracorporealPhotopheresisTreatmentforDermatologicalDiseasesChisa YamadaTransfusion Medicine, Department of Pathology, University of Michigan, Ann Ar-bor, Michigan, USA
SY5-04 AutologousHematopoieticStemCellTransplantation forTreatmentofSevereSystemicSclerosisMark WenerUniversity of Washington, Department of Laboratory Medicine & Division of Rheu-matology, USA
SY6-01 Theimprovementofacutekidneyinjurybyplasmadiafiltrationonsepsisanimalmodel Jun Xue Dept. of Nephrology, Huashan Hospital, Fudan University, Shanghai, China
SY6-02 Plasmaadiponectinlevelsinacuteliverfailurepatientstreatedwithplasmafil-trationwithdialysisandplasmaexchangeadYoshitaka UjiDepartment of Emergency and Gastroenterological Surgery, Shin-Koga Hospital, Fu-kuoka, Japan
SY6-03 PDFprocedure induceIL-10;acasereport Yutaka Eguchi Department of Critical and Intensive Care Medicine, Shiga University of Medical Science Shiga, Japan
SY6-04 Utilityofthenovelartificialliversupportcombinationtherapy,PDFwithhighflow-volumeCHDF Kota Kamizato Department of Anesthesiology and Intensive Care Medicine, University of the Ryukyus, Okinawa, Japan
SY6-05 Highflow-volumeplasmafiltrationwithdialysisandplasmaexchangewithdialy-sis Hajime Nakae Department of Emergency and Critical Care Medicine, Akita University Graduate School of Medicine, Japan
SY6-06 Continuousplasmafiltrationwithdialysis(CPDF)Takumi Taniguchi Department of Anesthesiology and Intensive Care Medicine, Kanazawa University, Kanazawa, japan
SY7-01 Comparisonofselectiveplasmaexchange,plasmadiafiltration,MARSandPro-metheussystemsintreatmentofliverfailureSokolov Alexey A.The Department of Anesthesiology and Reanimatology, North-Western State Medi-cal University named after I.I.Mechnikov, St.Petersburg, Russia
27
10月18日(金)
プログラム
10月19日(土)
プログラム
10月20日(日)
プログラム
特別企画
シンポジウム
ガイドライン
セッション
アフェレシス
マニュアルレクチャー
技術講習会
E-ISFA
Workshop
世界の
アフェレシス事情
一般演題
(英語口演)
一般演題
(日本語口演)
一般演題
(ポスター)
セミナー
索
引
10月18日(金)
SY7-02 SafetyManagementinPlasmaDiafiltrationMaki KagitaniBlood Purification Center, Osaka Medical College, Japan
SY7-03 Artificialliversupportforlivertransplantrecipientsduringperioperativeperi-odHironori HayashiDepartment of Surgery, Toyama Prefectural Central Hospital, Japan
SY7-04 MulticenterStudyofPlasmafiltrationwithdialysis(PDF)inPatientswithAcuteLiverFailure Yutaka Eguchi Department of Critical and Intensive Care Medicine, Shiga University of Medical Science Shiga, Japan
SY7-05 Clinicalapplicationandeffectanalysisofplasmadiafiltration(PDF)inpatientswithliverfailureYi Tian Dep.Infectious disease, the Second Xiangya Hospital, Central South University. Changsha, China
SA1-01 CurrentstatusofplasmaexchangeincriticalillpatientsinVietnamHien_Thi Thu HuynhCho Ray Hospital, Ho Chi Minh, Vietnam
SA1-02 Whatandhowwecanremovebytherapeuticapheresisusingadsorptiontechnol-ogy?Sergei N. PokrovskyNational Medical Research Center of Cardiology, Ministry of Health of Russian Fed-eration, Moscow, Russia
SA1-04 The improving effects of lipoprotein apheresis on cardiac vascular ultrasonicparametersDongliang ZhangThe Blood Purification Center of Nephrology Department, Peking University Inter-national Hospital, China
SA2-01 Severe Nephrotic Syndrome with Hyperthyroidism and Acute Renal FailureTreatmentwithPlasmapheresis and Immunosuppressive drug: TacrolimusDusit LumlertgulFaculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
SA2-02 EffectsofLDL-ApheresisinAdultRefractoryNephroticSyndromeandItsRe-producibilityHideki TakizawaThe Department of Nephrology, Teine Keijinkai Hospital, Sapporo, Japan
SA2-03 Plasmapheresis Reduces Mycophenolic Acid Concentration: A Study of FullAUC0-12Sudarat PiyasiridejNephrology unit, Department of Medicine, Chulalongorn University, Bangkok, Thai-land
29
10月18日(金)
プログラム
10月19日(土)
プログラム
10月20日(日)
プログラム
特別企画
シンポジウム
ガイドライン
セッション
アフェレシス
マニュアルレクチャー
技術講習会
E-ISFA
Workshop
世界の
アフェレシス事情
一般演題
(英語口演)
一般演題
(日本語口演)
一般演題
(ポスター)
セミナー
索
引
10月18日(金)
SA2-04 Immunoadsorption treatment of recurrentprimary focal segmentalglomerulo-sclerosis:Asinglecenterexperience.Hamza Naciri BennaniDepartment of Nephrology, Hemodialysis, Apheresis and Renal Transplantation, CHU Grenoble-Alpes, Grenoble, France
SA2-05 Apheresistherapyforsteroid-resistantidiopathicnephroticsyndrome:ReportonthreecasesHamza Naciri BennaniDepartment of Nephrology, Hemodialysis, Apheresis and Renal Transplantation, CHU Grenoble-Alpes, Grenoble, France
SA2-06 Rationale and StudyDesign of LDL apheresis-mediated Endothelial activationTherapytoSevere-PeripheralArteryDiseasestudy(LETS-PADstudy)Eiko UedaDepartment of Medical Science and Cardiorenal Medicine, Yokohama City Universi-ty Graduate School of Medicine, Kanagawa, Japan
EO1-01 NafamostatmesylateinhibitionofLZDmetabolismviaitsantioxidanteffectsNaohide KuriyamaDepartment of Anesthesiology & Critical Care Medicine, Fujita Health University, Toyoake, Japan
EO1-02 Themechanismofthedecreaseincardiacoutputmeasurementbytranspulmo-narythermodilutionhasbeenelucidated.Tomoyuki NakamuraDepartment of Anesthesiology and Critical Care Medicine, Fujita Health University School of Medicine, Toyoake, Japan
EO1-03 TreatmentofchronicHeavyMetalIntoxicationbyPlasmapheresis,PromiseorIllusion?Martin JansenInstitute of Clinical Chemistry and Laboratory Medicine, Faculty of Medicine, Uni-versity of Freiburg, Freiburg, Germany
EO1-04 ACaseseries-UseofTherapeuticPlasmaExchange(TPE)inthemanagementofPatientswithSnakebiteIndika de AlwisRegional Blood Centre, T H Ratnapura, Sri Lanka
EO1-05 Biocompatibilityandefficacyofself-anticoagulativechitosan-κ-carrageenancom-positehydrogel forsimultaneousendotoxinadsorptionandbacteriacapture insepticbloodYupei LiDepartment of Nephrology, West China Hospital, Sichuan University, Chengdu, Chi-na
EO1-06 Lactatepredicts the28-daysurvivalrate inpatientswithsepticshock treatedwiththecombinationofPMX-DHPandrTMMasafumi YamatoDepartment of Nephrology, National Hospital Organization, Osaka National Hospital, Osaka, Japan
SA3-01 Newsorbentsforthesimultaneousremovalofmostatherogenic,apoB100contain-inglipoproteinsandC-reactiveproteinElena UtkinaNational Medical Research Center of Cardiology, Ministry of Health of Russian Fed-eration, Moscow, Russia
SA3-02 Establishing Low-Density LipoproteinApharesisTolerability in Patientswith
PriorAnaphylactoidReactionstoLipidApharesisusingMagnesiumSulfate Ethan AlexanderUniversity of Kansas School of Medicine, Department of Clinical Pharmacology, Kan-sas City, Kansas, USA
SA3-03 ImpactofPCSK9inhibitorsonLDLapheresisSamir SahebDepartement of Endocrinology and Metabolism, Sorbonne University, Paris, France
(TheAPPROVEproject,acontrolledmulti-centerapheresistrial) Karl Winkler Institute of Clinical Chemistry and Laboratory Medicine, Faculty of Medicine, Uni-versity of Freiburg, Germany
PP1-01 TheprotectiveeffectofBifidobacteriumlongumR0175onD-galactosamine(Gal-N)-treatedratsKaicen WangThe First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
PP1-02 MAdCAM-1mediatesgut-derivedlymphocytetraffickingtoliverinprimaryscle-rosingcholangitismousemodelJiafeng XiaState Key Laboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
PP1-03 TheEvaluationandImprovementofaModifiedFluidizedBedBioreactorBasedonDiversion-TypeMicrocapsuleSuspensionforBioartificialLiverSystemsJuan LuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases,The First Affiliated Hospital, College of Medicine, Zhejiang University, China
PP1-04 FructusPsoraleae-inducedsevereliverinjuryandtreatmentwithtwoartificialliversupportsystems:AcaseseriesstudyZhongyang XieState Key Laboratory for Diagnosis and Treatment of Infectious Diseases,The First Affiliated Hospital, College of Medicine, Zhejiang University, China
PP1-05 Gastricmicrobiotaaltersaftershort-orlong-termethanolintakeJingjing WuLaboratory for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
PP1-06 5-lipoxygenase(5-LO)metabolicpathwayassociatedwithprognosisofhepatocel-lularcarcinoma:abigdataanalysisbasedonTCGADanhua ZhuState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
PP1-07 LactobacillushelveticusR0052alleviatesliverinjury,enhancesintestinalbarrier,modifiesgutmicrobiomeandmetabolomeinD-galactosamine-treatedratsQiangqiang WangThe First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
PP1-08 AdeliverysystemofPediococcuspentosaceusandtheireffectsofreducinghepat-icdamagefollowingacuteliverinjuryJiaojiao Xie The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China
33
Kazuaki Inoue 昭和大学藤が丘病院 消化器内科 Gastroenterology,Showa University Fujigaoka Hospital
PP2-01 BiochemicalEvaluationofProcessedAscites inPatientsUndergoingCell-FreeandConcentratedAscitesReinfusionTherapyHironori NakamuraDepartment of Nephrology, Shinonoi General Hospital, Nagano, Japan
PP2-04 多職種連携による胸腹水濾過濃縮専用装置(M-CART)の開発と臨床評価Development and clinical evaluation of an ascites filtration and concentrationequipmentbyinterprofessionalcollaboration福原 正史公立学校共済組合 四国中央病院 透析センター
PP2-05 顆粒球吸着療法後早期の潰瘍性大腸炎再燃と関連する因子Clinical factors associated with relapse of ulcerative colitis after granulo-cyte-monocyteadsorption浜崎 敬文東京大学医学部附属病院 血液浄化療法部